Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer

Oncologist. 2007 Dec;12(12):1467-9; author reply 1469-71. doi: 10.1634/theoncologist.12-12-1467.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality
  • Brain Neoplasms / secondary
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Disease-Free Survival
  • Female
  • Humans
  • Middle Aged
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Retrospective Studies
  • Survival Rate
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab